The Use of Generics in the Endo Pharmaceutical CaseĮndo has the patent on the original version of Opana ER, and they fought hard to keep the unique formulation off the market – so that other companies could not capitalize. While Endo agreed to stop making the drug and all shipments, they used generics as an end-run around the FDA request. The FDA urged the company to stop making and selling the drug and stated that the risks outweighed the benefits of the product. While the company claims the hard coating deters abuse, the FDA disagreed and urged the company to remove the product from the market. Regardless of their “coating,” addicts could cook the painkiller and then inject the cooked liquid. The new version that Endo released however had just a handful of new inactive ingredients – mainly the hard coating that made the pills harder to pulverize. The manufacturer advertised their product as one that was safe and effective for long-term treatment with opioids and claimed that their latest pill design prevented opioid abuse with their medication. Opana ER was released by the company back in 2012 as an opioid agonist to help manage severe pain. About the Endo Pharmaceutical Opana ER Product If you follow the news, you might have heard about the recent case involving Endo Pharmaceuticals.Įndo Pharmaceuticals, like many drug manufacturers, keep generic versions of their best-selling drugs on the market and then introduce new formulations to try and avoid lawsuits and complications with their brand label.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |